FDA Greenlights Thermo Fisher’s Test for New Lung Cancer Treatment

Thermo Fisher Scientific has achieved a significant milestone with the U.S. FDA’s approval of its Ion Torrent™ Oncomine™ Dx Target Test. This companion diagnostic is pivotal for identifying non-small cell lung cancer (NSCLC) patients eligible for Bayer’s novel treatment, HYRNUO™ (sevabertinib), a HER2/ERBB2-targeted therapy. This development could greatly impact the precision medicine landscape for NSCLC, a major cause of cancer mortality worldwide.

Non-small cell lung cancer dominates about 87% of lung cancer cases globally, with HER2 mutations indicating especially limited treatment options and poor prognosis. Bayer’s HYRNUO™ has received FDA approval for treating adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 TKD mutations. This approval, alongside Thermo Fisher’s companion diagnostic, addresses persistent gaps in precision medicine caused by testing and infrastructure delays. Such advancements could dramatically improve patient outcomes, historically hampered by a lack of timely or accessible targeted therapy.

The Oncomine Dx Target Test’s FDA approval not only enhances diagnostic capabilities but also highlights Thermo Fisher’s role in advancing companion diagnostics. By facilitating the identification of appropriate candidates for Bayer’s HYRNUO™ therapy, this collaboration promises to elevate precision treatment strategies globally, impacting the lives of countless lung cancer patients. With comprehensive reimbursement coverage in multiple regions, Thermo Fisher and Bayer are poised to set new standards in oncological care.